Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06990269 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 35 → 83 locationsv10
  2. Trial sites expanded: 27 → 35 locationsv9
  3. Trial sites expanded: 24 → 27 locationsv8
  4. Primary completion pushed from Sep 30, 2027 to Feb 28, 2030 Trial sites expanded: 17 → 24 locations · Completion pushed from Dec 2027 to Aug 30, 2030v7 Show 2 more changesShow less
    • Trial sites expanded: 17 → 24 locations
    • Completion pushed from Dec 2027 to Aug 30, 2030
  5. 2 versions Re-verified since Feb 16, 2026, no change to tracked fieldsv5-v6
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 17 · Primary completion date: Sep 2027 to Sep 30, 2027 · Start date changed from estimate of Nov 2025 to Nov 10, 2025v4 Show 3 more changesShow less
    • Study sites: 0 to 17
    • Primary completion date: Sep 2027 to Sep 30, 2027
    • Start date changed from estimate of Nov 2025 to Nov 10, 2025
  2. Start date: Aug 2025 to Nov 2025v3
  3. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
Trial Details
NCT Number NCT06990269
Lead Sponsor ADARx Pharmaceuticals, Inc.
Conditions Geographic Atrophy Secondary to Age-related Macular Degeneration
Enrollment 240 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov